RBC Capital upgraded shares of Chemours (CC) to Outperform from Sector Perform in a note Friday, raising the price target on the stock to $40 from $28 per share.
Analysts said the firm is upgrading the stock based on the TiO2 margin recovery and TSS strength.
"We are raising FY24 EBITDA estimates to $1.17B from $1.15B on slightly higher H2/24 TiO2 volumes," the analysts wrote. "CC's TT EBITDA appears at trough with prices (~$3,200-$3,600) near marginal cost in Asia (Chinese Sulfate had negative margins 4Q/22-1Q/23). Per TZMI, avg. 2024 TiO2 pricing will be slightly lower, but with much lower costs due to increased feedstock availability driving significant EBITDA margin expansion."
"Given easy 2023 comps and potential tariffs on Chinese TiO2 in Europe, we expect slight volume growth for TT in 2024," they added.
The analysts also note that TSS is performing well with continued OPTEON adoption ahead of the 2024 HFC step-down.
"We see CC's expeditious and successful settling of legacy liabilities as meaningfully de-risking CC stock, which could drive 1-3x turns of multiple expansion," the analysts concluded.